Guardian Pharmacy Services, Inc.(GRDN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,606 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
GRDN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Guardian Pharmacy Services, Inc. (GRDN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GRDN at 47.3/100 on a 32-signal composite quality model, placing it at rank #1,606 of 2,879 stocks — the bottom half of the AI-ranked universe. GRDN scores in the top quartile across earnings quality (96.6), balance sheet strength (86.5). Areas of concern include institutional flow (1.4) and revenue growth (4.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Guardian Pharmacy Services, Inc. reports quarterly revenue of $336.6M, net income of $13.3M, an operating margin of 5.3%. Top institutional holders of GRDN by reported 13-F value include FMR, WELLINGTON MANAGEMENT GROUP LLP, BlackRock,, based on the most recent SEC filings. GRDN trades on the NYSE exchange and files with the SEC under CIK 1802255. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GRDN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Guardian Pharmacy Services, Inc. directly from SEC EDGAR. Guardian Pharmacy Services, Inc.'s 13F Pro composite quality score has ranged between 31 and 49 since 2026, currently 47.3 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.
Revenue
Q1 2026
$336.6M
Net Income
Q1 2026
$13.3M
Free Cash Flow
Q1 2026
$6.1M
Operating Margin
Q1 2026
5.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+17.9% YoYNet Income
+144.7% YoYOperating Income
+215.5% YoYTotal Assets
+28.6% YoYTotal Debt
Op. Cash Flow
+73.0% YoY| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | $1.45B +17.9% | $1.23B |
| Net Income | $49.2M +144.7% | $-110.0M |
| Operating Income | $72.7M +215.5% | $-62.9M |
| Total Assets | $412.7M +28.6% | $320.8M |
| Total Debt | $0.00 | $0.00 |
| Operating Cash Flow | $100.3M +73.0% | $58.0M |
AI Insight: GRDN Financial Trends
Revenue grew 2.4% YoY to $337M in Q1 2026 while net income surged to $13M from $9M, but operating cash flow collapsed to $6M — the weakest in five quarters.
• Revenue rose sequentially from $329M in Q1 2025 to $337M in Q1 2026, a 2.4% year-over-year gain.
• Net income improved from $9M in Q1 2025 to $13M in Q1 2026, and operating income expanded from $13M to $18M.
• Operating cash flow dropped sharply to $6M in Q1 2026 from $35M in Q4 2025 — the lowest reading across all reported quarters.
⚠ Operating CF of $6M in Q1 2026 vs. $18M operating income signals a large working-capital drag; sustainability is unclear.
⚠ Debt reported at $0M in Q4 2025 vs. $34M in Q3 2024; debt levels in Q1 2026 are unreported — monitor for re-leveraging.
AI Insight: GRDN Ratio Trends
Profitability surged in Q4 2025 then partially retraced, but Q1 2026 margins still sit well above the Q2 2025 trough.
• Operating margin expanded from a Q2 2025 low of 3.6% to 7.7% in Q4 2025, before settling at 5.2% in Q1 2026.
• Net profit margin followed the same arc: 2.6% in Q2–Q3 2025, peaking at 5.3% in Q4 2025, then 4.0% in Q1 2026.
• ROA recovered from a 10.1% trough in Q2–Q3 2025 to 12.5% in Q1 2026, near the 12.4% TTM level.
⚠ Q4 2025 spike in operating margin (7.7%) and ROA (20.3%) looks like a one-off; Q1 2026 reversion warrants monitoring for sustainability.
⚠ ROE, ROIC, and D/E are entirely absent — capital structure and return-on-equity dynamics cannot be assessed from available data.
Get alerted when GRDN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Guardian Pharmacy Services, Inc. including:
Top Institutional Holders of GRDN
FMR LLC
$88.9M2,359,357 shWELLINGTON MANAGEMENT GROUP LLP
$66.5M1,765,119 shBlackRock, Inc.
$66.1M1,756,374 shWoodline Partners LP
$49.2M1,306,318 shBROWN ADVISORY INC
$47.4M1,259,174 shVANGUARD CAPITAL MANAGEMENT LLC
$46.2M1,225,543 shValiant Capital Management, L.P.
$44.7M1,186,658 shTimesSquare Capital Management, LLC
$40.6M1,077,474 shBoston Partners
$38.4M1,017,683 shFRANKLIN RESOURCES INC
$35.9M952,952 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $88.9M | 2,359,357 |
| WELLINGTON MANAGEMENT GROUP LLP | $66.5M | 1,765,119 |
| BlackRock, Inc. | $66.1M | 1,756,374 |
| Woodline Partners LP | $49.2M | 1,306,318 |
| BROWN ADVISORY INC | $47.4M | 1,259,174 |
| VANGUARD CAPITAL MANAGEMENT LLC | $46.2M | 1,225,543 |
| Valiant Capital Management, L.P. | $44.7M | 1,186,658 |
| TimesSquare Capital Management, LLC | $40.6M | 1,077,474 |
| Boston Partners | $38.4M | 1,017,683 |
| FRANKLIN RESOURCES INC | $35.9M | 952,952 |
More Healthcare Companies
View all Healthcare →Put GRDN on your watchlist
Track score changes the day Guardian Pharmacy Services, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GRDN a good stock to buy?
13F Pro's AI-powered analysis of Guardian Pharmacy Services, Inc. (GRDN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GRDN are available on the GRDN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own GRDN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GRDN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Guardian Pharmacy Services, Inc.'s investment landscape.